Trial ID or NCT#
The primary objective of this study is to prevent chronic graft versus host disease in stem cell transplant patients. The drug being studied will be administered in the hopes of preventing cGVHD, and the use of steroids to treat it.
A Randomized Phase 2 Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation
Contact us to find out if this trial is right for you.